{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:31Z","timestamp":1753891891324,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm-ALL). We report a case of a 51-year-old female patient who developed acute lymphoblastic leukemia 14 years after being diagnosed with diffuse large B-cell lymphoma (DLBCL). The patient was unresponsive to conventional chemotherapy for acute lymphoblastic leukemia (ALL) and achieved remission with a combination of sorafenib and decitabine based on the molecular biology characteristics of her B-ALL.<\/jats:p>","DOI":"10.3389\/fonc.2024.1329279","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:57:23Z","timestamp":1714107443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine"],"prefix":"10.3389","volume":"14","author":[{"given":"Mengci","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.blre.2023.101070","article-title":"\u2018Secondary\u2019 Acute lymphoblastic\/lymphocytic leukemia - done playing second fiddle","volume":"60","author":"Riazat-Kesh","year":"2023","journal-title":"Blood Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000925","article-title":"Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes","volume":"3","author":"Saygin","year":"2019","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7150\/jca.76719","article-title":"Therapy-related acute lymphoblastic leukaemia has a unique genetic profile compared to de novo acute lymphoblastic leukaemia","volume":"13","author":"Kook","year":"2022","journal-title":"J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41408-022-00680-y","article-title":"Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma","volume":"12","author":"Parrondo","year":"2022","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.08.011","article-title":"Mll partner genes in secondary acute lymphoblastic leukemia: report of a new partner prrc1 and review of the literature","volume":"38","author":"Douet-Guilbert","year":"2014","journal-title":"Leukemia Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200311","article-title":"Therapy-related acute lymphoblastic leukemia","volume":"103","author":"Ribera","year":"2018","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.lrr.2022.100315","article-title":"Lenalidomide induced secondary acute lymphoblastic leukemia in a multiple myeloma patient: A case-report","volume":"17","author":"Khan","year":"2022","journal-title":"Leukemia Res Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030412","article-title":"Clinical characteristics and prognosis of secondary acute lymphoblastic leukemia in patients with multiple myeloma during long-term thalidomide maintenance","volume":"13","author":"Liu","year":"2023","journal-title":"J Personalized Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa109","article-title":"Lenalidomide-associated secondary B-lymphoblastic leukemia\/lymphoma-a unique entity","volume":"154","author":"Germans","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100358","DOI":"10.1016\/j.lrr.2022.100358","article-title":"Therapy-related B-lymphoblastic leukemia after multiple myeloma","volume":"18","author":"Kallen","year":"2022","journal-title":"Leukemia Res Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/10428194.2015.1040013","article-title":"Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic Malignancy","volume":"57","author":"Kelleher","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.09.011","article-title":"Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis","volume":"39","author":"Giri","year":"2015","journal-title":"Leukemia Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100584","DOI":"10.1016\/j.blre.2019.06.001","article-title":"Therapy-related acute lymphoblastic leukemia: where do we stand with regards to its definition and characterization","volume":"37","author":"Aldoss","year":"2019","journal-title":"Blood Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v7i12","article-title":"Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes","volume":"7","author":"Messina","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1758387","article-title":"Pax5 and tdt-negative B-acute lymphoblastic leukemia with unusual genetic mutations: A case report","volume":"12","author":"Aladily","year":"2022","journal-title":"Avicenna J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12885-023-10724-6","article-title":"Dnmt3a low-expression is correlated to poor prognosis in childhood B-all and confers resistance to daunorubicin on leukemic cells","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.06.034","article-title":"[Clinical characteristics and prognostic significance of bcor\/bcorl1 gene mutation in patients with myelodysplastic syndromes]","volume":"28","author":"Cen","year":"2020","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5473197","DOI":"10.1155\/2017\/5473197","article-title":"Epigenetic guardian: A review of the DNA methyltransferase dnmt3a in acute myeloid leukaemia and clonal haematopoiesis","volume":"2017","author":"Chaudry","year":"2017","journal-title":"BioMed Res Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1309\/AJCPYWC6AQC7BAVJ","article-title":"Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review","volume":"133","author":"Chen","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26735","article-title":"Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis","volume":"118","author":"Abdulwahab","year":"2012","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (All): long-term follow-up of the gimema all 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.935.935","article-title":"Secondary acute lymphoblastic leukemia after primary solid organ Malignancy: A seer analysis of incidence and outcomes","volume":"124","author":"Swaika","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01636.x","article-title":"Acute lymphoblastic leukaemia occurring as second Malignancy: report of the gimema archive of adult acute leukaemia. Gruppo italiano malattie ematologiche Maligne dell\u2019adulto","volume":"106","author":"Pagano","year":"1999","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10046","article-title":"11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop","volume":"33","author":"Bloomfield","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, nccn clinical practice guidelines in oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Cancer Network"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: crs and icans after car T-cell therapy for all","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplantation"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1329279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:57:26Z","timestamp":1714107446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1329279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":26,"alternative-id":["10.3389\/fonc.2024.1329279"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1329279","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"article-number":"1329279"}}